Pseudonymised Data Should Fuel Orphan Drug Discovery, but Criteria and Overseas Usage Must Be Discussed: JPMA

The Japan Pharmaceutical Manufacturers Association (JPMA) welcomes a recently enacted amendment of the next-generation medical infrastructure law, which creates a new category of information called “pseudonymized medical data.” Such data will drive drug discoveries in the rare disease space, the...read more